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Abstract
Introduction: Inhabitants living in areas with endemic dietary iodine intake deficiency develop nodular goitre. The aim of our study 
was to evaluate thyroid morphology and function among adults residing in Lower Silesia and to assess the effect on the thyroid gland of 
an iodine-based contrasting agent administered during a cardiac intervention procedure.
Materials and methods: The first part of the study (evaluation of thyroid gland) was carried out on 120 subjects (78 men and 42 women). 
From among this group, invasive cardiac procedures were performed on 60 subjects (38 men and 22 women) during the second part of 
the study. Endocrine tests were repeated one, three, and six months after the invasive procedure.
Results: 1) Within the studied group, pathological changes in thyroid morphology were found in 49.1%, and thyroid function disturbances 
in 9.3%, of all subjects. 2) A decrease in TSH concentration with a corresponding increase in fT3 concentration was seen at the second visit 
(four weeks after iodine administration) leading to the diagnosis of hyperthyroidism in 15% of subjects. 
Conclusions: 1) Considering the multitude of silent thyroid pathologies, particular care is required before administering an iodine-based 
medium. 2) It is reasonable and advisable to monitor TSH and fT3 levels before and at four weeks after administration of an iodine-containing 
contrast agent. 3) Thyroid morphology and function disturbances after iodine administration do not necessitate treatment, as they are of 
transient character and only require monitoring. (Endokrynol Pol 2012; 63 (4): 294–299)
Key words: thyroid gland, nodular goitre, iodine intake deficiency, invasive cardiac procedures
Streszczenie
Wstęp: Wiadomym jest, że mieszkańcy terenów ubogich w jod rozwijają szereg niemych klinicznie patologii tarczycy. Celem badania 
była ocena morfologii i funkcji tarczycy w populacji dorosłych mieszkańców Dolnego Śląska oraz ocena wpływu na gruczoł tarczowy 
jednorazowo podanej dawki jodu w postaci kontrastu w trakcie kardiologicznych procedur interwencyjnych.
Materiały i metody: Do pierwszej części badania, której celem była ocena morfologii i funkcji tarczycy u zdrowych mieszkańców Dolne-
go Śląska zakwalifikowano 120 osób (78 mężczyzn i 42 kobiety). Z tej grupy wyłoniono 60 osób (38 mężczyzn i 22 kobiety) które, z racji 
wskazań do inwazyjnych zabiegów kardiologicznych (koronarografii/PTCA), obciążono dużą dawką jodu oraz przeprowadzano u nich 
ocenę tyreologiczną po 1, 3 i 6 miesiącach od interwencji.
Wyniki: 1) Patologiczne zmiany w morfologii tarczycy stwierdzono u 49,1%, zaburzenia dotyczące stężeń hormonów tarczycy i przeciwciał 
przeciwtarczycowych stwierdzono u 17,6%, które przekładały się na zaburzenia funkcji tarczycy u 9,3% zdrowych tyreologicznie miesz-
kańców Dolnego Śląska. 2) Największe zmiany: obniżenie stężenia TSH i wzrost stężenia fT3 były widoczne 4 tygodnie po obciążeniu 
jodem, prowadząc do rozpoznania nadczynności tarczycy u 15% pacjentów.
Wnioski: 1) Z uwagi na dużą ilość klinicznie niemych zaburzeń morfologii i funkcji tarczycy ważna jest jej dokładna ocena przed obcią-
żeniem chorego jodem. 2) Jest poparte dowodami i polecane monitorowanie stężenia TSH i fT3 przed i 4 tygodnie po obciążeniu chorego 
jodem. 3) Zaburzenia morfologii i funkcji tarczycy po podaniu pacjentowi jodu mają charakter przemijający, wymagają monitorowania, 
ale nie leczenia. (Endokrynol Pol 2012; 63 (4): 294–299)
Słowa kluczowe: tarczyca, wole guzowate, niedobór jodu, kardiologiczne procedury interwencyjne
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Introduction
Nodular goitre presents as a spectrum of pathology 
in thyroid morphology and function that is strongly 
associated with iodine deficiency, to date the best 
examined epidemiological risk factor involved 
in its pathogenesis. It has been observed that the 
prevalence of nodular goitre in a given population is 
strongly influenced by dietary iodine uptake. Iodine 
is a proven thyroid function regulator, influencing 
thyroid size, thyroid hormone levels, and thyroglobu-
lin blood concentration, and is thus engaged in the 
organism’s metabolism [1–5]. According to ultrasono-
graphic thyroid gland screening population studies, 
the prevalence of nodular goitre in the adult popula-
tion ranges between 30% and 40% among women, 
and 20% and 30% among men, residing in regions 
deficient in iodine [6].
It is well known that inhabitants living in regions 
characterised by insufficient dietary iodine intake tend 
to develop nodular goitre, and that this is not observed 
in subjects with sufficient iodine supplementation, 
including among residents of Poland where efficient 
(according to literature) obligatory prophylactic iodine 
supplementation programmes have been instituted 
since 1997 [7, 8].
Lastly, the number of invasive cardiac interventions 
performed has been steadily rising in Lower Silesia. In-
travenous contrast agents routinely used as a standard 
part of coronary angioplasty are iodine-based. Such 
a single dose of iodine administered far exceeds the 
recommended daily allowance for adults, which may 
interfere with normal thyroid gland function. Under 
normal conditions, the adult person’s iodine require-
ment is estimated to be 0.15–0.20 mg per 24 hours 
[7, 9, 10].
In the literature, there is a glaring lack of current 
epidemiological data on the presence of thyroid goitre 
among adult inhabitants of Lower Silesia as well as 
a lack of data on the effects on thyroid morphology and 
function after the administration of such a high single 
dose of iodine as part of an interventional procedure. 
Lower Silesia was recently recognized as an endemic 
region of nodular goitre.
Aim of our study
To evaluate the effects on the thyroid gland morphology 
and function produced by administration of a single 
dose of iodine-based contrast agent during a cardiac 
intervention procedure in adults in Lower Silesia com-
pared to the baseline morphology and function of the 
thyroid gland as assessed prior to the intervention.
Materials and methods
The first part of the study was carried out on 120 
subjects (78 men and 42 women) aged 59.7 ± 7.8 
years visiting an Outpatient Cardiology Clinic in 
the 4th Military Hospital in Wrocław over a period of 
six months (2009/2010). The demographic and clini-
cal characteristics of the study group are set out in 
Tables I and II. None of the subjects included in the 
study had a previous history of thyroid disorders, 
and all had normal thyroid function parameters at 
the beginning of the study.
Prior to cardiac procedures using iodine-based 
contrast agents, the following tests were performed:
 — thyroid hormone profile (TSH, fT3, fT4, TT3, TT4);
 — anti-thyroid antibodies (TPO, ATG, TSHR antibodies);
 — thyroid ultrasound;
 — iodine uptake capacity using scintigraphy of thyroid 
gland;
 — physical examination;
 — urine iodine excretion.
From the group of 120 subjects previously qualified, 
60 subjects (38 men and 22 women) were selected to 
the second part of the study. One man was excluded 
because of a new diagnosis of thyrotoxicosis in the 
course of Graves’ disease. In the group of 59 subjects 
aged 58.7 ± 8.8 years, invasive cardiac procedures i.e. 
Table I. Demographic data of the study group
Table I. Dane demograficzne badanej grupy
Parameter Entire group Male Female
Number of subjects 120 78 42
Mean age [years] 59.7 ± 7.8 58.0 (± 8.4) 62.4 (± 6.0)
Mean height [m] 1.7 (± 0.1) 1.7 (± 0.1) 1.6 (± 0.1)
Mean weight [kg] 82.2 (± 18.4) 89.9 (± 18.3) 69.1 (± 9.5)
Mean BMI [kg/m2] 28.5 (± 4.9) 29.3 (± 5.0) 27.2 (± 4.6)
Mean thyroid iodine uptake [%] 24.3 (± 8.1) 23.4 (± 8.7) 25.9 (± 7.1)
Mean thyroid volume [mL] 15.6 (± 8.4) 18.4 (± 9.0) 10.8 (± 4.3)
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coronarography (41 subjects) and coronarography with 
PTCA (18 subjects), were performed. The single dose 
of iodine administered during the procedure ranged 
between 37 grams and 222 grams (Table III). Endocrine 
thyroid tests were repeated at one, three, and six months 
following the invasive procedure.
The study was approved by the local bioethics com-
mittee. All subjects enrolled in the study were provided 
with written information on the purpose and design 
of the study.
Statistical analysis
Statistical analysis was performed using the Statistica 
program 6.0. Differences between variables were as-
sessed using the Student t-test. Pearson correlation 
and Spearman rank correlation were used in order to 
find relationships between variables. Comparison of 
two patient groups was made using the Tukey test and 
t-student test. All results were found to be statistically 
significant at p < 0.05.
Results
Changes in thyroid echogenicity, echostructure and 
changes in thyroid volume are depicted in Figure 1. 
At the end of our assessment, 34 patients (57.6%) had 
heterogeneous thyroid echostructure; newly formed 
nodules had a diameter of less than 1 cm, while the 
nodules which were initially present at the beginning 
of the study were found to have increased in size by 
more than 1 cm.
The volume of thyroid increased by about 1.5 ml af-
ter iodine administration, with maximum volume noted 
at the second visit, then, beginning at the third visit, the 
thyroid volume gradually decreased, but in none of the 
cases did it return to the original size noted at the first 
visit. Thyroid volume correlated positively with the 
size and number of thyroid nodules and negatively 
with TSH concentration — mostly between visits 1 and 
2. Greater volume of the thyroid gland was associated 
with an increased neck discomfort.
Table II. Clinical data of the studied group
Tabela II. Dane kliniczne badanej grupy
Parameter Number  
of subjects
Number  
of male 
Number  
of female
Subjects included in the study 120 78 42
Subjects with thyroid pathology 59 (49.1%) 45 (37.5%) 14 (11.6%)
Changes in thyroid morphology Physical  
examination
First stage goitre (palpable  
but not visible)
22 (18.3%) 16 (13.3%) 6 (5%)
Second stage goitre (visible at 
normal anatomical position of 
neck)
6 (5%) 4 (3.3%) 2 (1.7%)
Ultrasound 
examination
Heterogeneous echogenicity  
of the thyroid gland
47 (39.1%) 29 (24.2%) 18 (15%)
Heterogeneous echostructure  
of thyroid gland
69 (57.5%) 46 (38.3%) 23 (19.2%)
Nodules of the thyroid gland (all) 44 (37%) 30 (25%) 14 (12%)
Numerous nodules (diameter  
< 1 cm and > 1 cm)
28 (23.5%) 20 (16.7%) 8 (6.6%)
Single nodule (diameter > 1 cm) 4 (3.3%) 2 (1.65%) 2 (1.65%)
Single nodule (diameter < 1 cm) 12 (10.2%) 8 (6.7%) 4 (3.3%)
Changes in antibodies  
(increase)
Anti-TSHR antibodies 1 (0.8%) 1 (0.8%) –
Anti-TPO antibodies 4 (3.3%) 2 (1.6%) 2 (1.6%)
Anti-ATG antibodies 8 (6.6%) 2 (1.6%) 6 (5%)
Changes in hormones ≠fT3 or fT4 and ´  TSH 10 (8.3%) 5 (4,2%) 5 (4.2%)
≠TT3 10 (8.3%) – 10 (8.3%)
≠TT4 8 (6.6%) 4 (3.3%) 4 (3.3%)
≠TT3 and TT4 8 (6.6%) 8 (6.6%) –
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The changes in thyroid function observed are il-
lustrated in Figure 2 below.
A decrease in TSH concentration with a correspond-
ing increase in fT3 concentration was seen at the second 
visit (four weeks after iodine administration) leading to 
the diagnosis of hyperthyroidism in nine subjects (15%). 
Subclinical hyperthyroidism was diagnosed in three sub-
jects. In six patients, clinically evident hyperthyroidism 
with symptoms of hypermetabolic state, mainly present-
ing as an arrhythmia during nights, was observed.
During the third visit, fT3 and fT4 concentrations re-
turned to their normal range, although the level of TSH 
took longer to normalise than the other two parameters; 
Table III. Information about administered doses of iodine
Tabela III. Informacje o podawanych dawkach jodu
Parameter Entire group Male Female
Number of subjects 59 37 22
Number of patients undergoing coronarography without PTCA 41 25 16
Number patients undergoing coronarography and PTCA 18 12 6
Mean dose of iodine administered during cardiac procedure [g] 60.75 (± 43.72) 63.62 (± 38.12) 55.92 (± 53.28)
Figure 1. Changes in echostructure, echogenicity and volume of 
the thyroid gland at visits scheduled at one, three and six months 
after intervention with iodine administration; *#statistically 
significant changes of illustrated parameters
Rycina 1. Zmiany w echostrukturze, echogeniczności i objętości 
gruczołu tarczowego wyjściowo oraz po 1, 3 i 6 miesiącach od 
podania jodu; *#statystycznie istotne zmiany ilustrowanych 
parametrów
Figure 2. Changes expressed in thyroid hormone concentrations 
and anti-thyroid antibodies at visits scheduled at one, three 
and six months after intervention with iodine administration; 
*#statistically significant changes of illustrated parameters
Rycina 2. Zmiany dotyczące stężenia hormonów tarczycy oraz 
przeciwciał przeciwtarczycowych wyjściowo oraz po 1, 3 i 6 mie- 
siącach od podania jodu; *#statystycznie istotne zmiany ilustrowanych 
parametrów
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of these, one was a case of subclinical hyperthyroidism, 
one of hyperthyroidism, and one subject had subclinical 
hypothyroidism.
After six months, during the last (fourth) visit, we 
observed low TSH levels (subclinical hyperthyroidism) 
in two cases and in one we observed elevated TSH 
(subclinical hypothyroidism). In the remainder of the 
patients, thyroid function returned to the baseline status 
seen before iodine administration.
A comparison of the two patient groups produced 
the following observations regarding morphology of 
thyroid, iodine doses, iodine uptake and patient gender.
In the group with changes noted at the beginning 
of the study, statistically important differences in fT4 
concentration were seen. In the group with initially 
normal thyroid morphology, fT3 changes were mostly 
observed. In the group that received more than 40 grams 
of iodine, only changes in TSH and anti-TPO antibody 
concentrations were seen, whereas in the group that 
received less than 40 grams of iodine, statistically sig-
nificant changes in TSH, fT3, fT4 and anti-ATG antibody 
concentrations were noted.
All morphological and functional thyroid changes 
described in the study occurred in those subjects in 
whom the rate of thyroid iodine uptake was more than 
20%. In those cases where uptake was less than 20%, 
there were no changes seen in the thyroid status.
Statistically important changes in the TSH concen-
tration persisted longer in men compared to women, but 
there were no other noteworthy differences between 
the genders.
Discussion
In the period between 1981 and 2006, a significant 
number of articles addressed the effects of iodine ad-
ministration during interventional cardiac procedures 
on the thyroid gland. Differences between these studies 
mostly concerned the various methods of assessment of 
thyroid morphology and parameters of thyroid func-
tion, the quantity of administered iodine, the period of 
time following the procedure during which the thyroid 
was periodically assessed, as well as the demographics 
of the observed populations [11–15].
The work of Fassbender et al. did not reveal any 
clinical or laboratory features of hyperthyroidism 
as evidenced by TSH, TT3, TT4, fT4 concentrations 
even though the population under study came from 
an iodine-deficient region with endemic nodular goi-
tre. Additionally, the value of the Fassbender study 
was limited by the small sample groups of patients 
examined. The main difference was with respect to the 
much shorter follow-up patient time after the cardiac 
intervention procedure (only three weeks), while in our 
work we focused on an expanded panel of laboratory 
parameters in which we noted the greatest changes in 
TSH and fT3 concentrations at four weeks after iodine 
administration.
In the Gartner et al. study, thyroid was assessed 
on a daily basis during the first seven days following 
iodine administration in all subjects qualified; while hy-
perthyroidism was observed in none of the cases, tran-
sient subclinical hypothyroidism was seen. The main 
distinctions between this study and our own mainly 
concerned differences in the populations under inves-
tigation (inhabitants of regions with sufficient iodine 
supplementation, small group of examined subjects: 16 
persons vs. 120 persons from an iodine-deficient region) 
as well as a difference in the employed methodology.
In the two Russian works (Dedov et al., Egorov et 
al.), changes in the levels of thyroid hormones measured 
after iodine administration were noted. However, there 
was no investigation accompanying changes in thyroid 
morphology, which distinguished this study from our 
own, where we focused on both thyroid function and 
morphology [13, 14]. Hyperthyroidism was observed 
in half as many subjects, similarly as in our study, and 
interestingly in their study hypothyroidism was more 
frequently noted than in our own; the possible explana-
tion for this difference could be the more heterogeneous 
group of patients included in the Russian study. As in 
our work, clinical manifestations of thyroid dysfunction 
were present. Significant changes in thyroid hormone 
levels in both of their articles were also observed at four 
weeks following iodine administration.
These common findings lead to a conclusion that 
iodine administration results in changes in thyroid func-
tion, and the range of these changes depends more on 
the baseline thyroid status at the time before adminis-
tration (with regard to morphology and function) than 
on the doses of iodine administered.
Nolte et al. [15] went a step further, by administer-
ing a short course of antithyroid drugs before and after 
coronarography to patients with abnormal thyroid 
gland morphology, as a preventive measure against 
hyperthyroidism in the group of treated patients, while 
those in the control group with normal native thyroid 
gland did not receive such prophylactic treatment. In 
the Nolte et al. study there were no newly recognized 
cases of hyperthyroidism within the treated group. 
Administration of prophylactic thyreostatics in those 
with thyroid dysfunction is an interesting approach 
that warrants further investigation.
In the article by Hintze et al., hyperthyroidism 
was noted only in a fraction of the population studied 
(0.25%) despite the similarities among the studied 
groups of subjects (chosen non-selectively and from 
an endemic region). This finding contrasted with our 
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own, where hyperthyroidism was observed in as many 
as 15% of subjects; thus, conclusions drawn from this 
work completely differ with those that stem from our 
work, as well as those from all articles cited above.
One unique feature in this study is that previously, 
no extended assessment of thyroid status had been 
performed on the adult population of Lower Silesia.
Conclusions
The prevalence of unrecognised silent thyroid pa-
thologies in patients from endemic areas warrants the 
exercise of particular judiciousness when making the 
decision to administer iodine during a diagnostic/thera-
peutic procedure.
In those cases where the thyroid status is unknown, 
it is advisable that clinicians carefully consider the diag- 
nostic/therapeutic procedure chosen and, preferably, 
choose one that does not include iodine contrast agent.
An important aspect is monitoring thyroid function 
(TSH and fT3 level) before and four weeks after iodine-con-
taining contrast agent administration, and informing 
patients about possible and reversible symptoms.
Thyroid morphology and function disturbances 
after iodine administration are of a transient character, 
and require monitoring but not necessarily treatment.
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